{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:42:53Z","timestamp":1790174573326,"version":"4.1.0"},"reference-count":88,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization among the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy.<\/jats:p>","DOI":"10.1515\/pp-2017-0003","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T06:01:27Z","timestamp":1491631287000},"page":"63-72","source":"Crossref","is-referenced-by-count":38,"title":["Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice"],"prefix":"10.1515","volume":"2","author":[{"given":"Kurt","family":"Van der Speeten","sequence":"first","affiliation":[{"name":"Department of Medicine and Life Sciences , Hasselt University , Hasselt , Belgium"},{"name":"Department of Surgical Oncology , Ziekenhuis Oost-Limburg , Schiepse Bos 6, 3600 Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieselotte","family":"Lemoine","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology , Ziekenhuis Oost-Limburg , Genk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sugarbaker","sequence":"additional","affiliation":[{"name":"Washington Cancer Institute, Washington Hospital Center , Washington DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"2025120909204647799_j_pp-2017-0003_ref_001_w2aab3b7c10b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 2014;111:1500\u20138.","DOI":"10.1038\/bjc.2014.419"},{"key":"2025120909204647799_j_pp-2017-0003_ref_002_w2aab3b7c10b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, Bruin S, Boot H, Van Slooten G, Van Tinteren H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426\u201332.","DOI":"10.1245\/s10434-008-9966-2"},{"key":"2025120909204647799_j_pp-2017-0003_ref_003_w2aab3b7c10b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, Van Ruth S, De Bree E, Van Sloothen GW, Van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343.","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909204647799_j_pp-2017-0003_ref_004_w2aab3b7c10b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140\u20138.","DOI":"10.1016\/j.ejca.2013.05.027"},{"key":"2025120909204647799_j_pp-2017-0003_ref_005_w2aab3b7c10b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study. Ann Surg Oncol 2015;22:1570\u20135.","DOI":"10.1245\/s10434-014-4157-9"},{"key":"2025120909204647799_j_pp-2017-0003_ref_006_w2aab3b7c10b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Marcotte E, Dube P, Drolet P, Mitchell A, Frenette S, Leblanc G, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: A survival analysis. World J Surg Oncol 2014;12:332.","DOI":"10.1186\/1477-7819-12-332"},{"key":"2025120909204647799_j_pp-2017-0003_ref_007_w2aab3b7c10b1b6b1ab2b1b7Aa","unstructured":"Sideris L, Mitchell A, Drolet P, Leblanc G, Leclerc YE, Dube P. Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg 2009;52:135\u201341."},{"key":"2025120909204647799_j_pp-2017-0003_ref_008_w2aab3b7c10b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. J Clin Oncol 2009;27:6237\u201342.","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025120909204647799_j_pp-2017-0003_ref_009_w2aab3b7c10b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370\u20137.","DOI":"10.1245\/s10434-010-1039-7"},{"key":"2025120909204647799_j_pp-2017-0003_ref_010_w2aab3b7c10b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, Asencio JM, Alvarez De Sierra P, Atahualpa Arenas F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: Upfront therapy, at first recurrence, or later? Eur J Surg Oncol. 2013;39:1109\u201315.","DOI":"10.1016\/j.ejso.2013.06.022"},{"key":"2025120909204647799_j_pp-2017-0003_ref_011_w2aab3b7c10b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Clarisse Eveno MP. Randomized controlled trials evaluating cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in prevention and therapy of peritoneal metastasis: A systemic review. Pleura and Peritoneum 2016;1:169\u201382.","DOI":"10.1515\/pp-2016-0027"},{"key":"2025120909204647799_j_pp-2017-0003_ref_012_w2aab3b7c10b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1,290 patients. Cancer 2010;116:5608\u201318.","DOI":"10.1002\/cncr.25356"},{"key":"2025120909204647799_j_pp-2017-0003_ref_013_w2aab3b7c10b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69\u201376.","DOI":"10.1016\/S1470-2045(05)70539-8"},{"key":"2025120909204647799_j_pp-2017-0003_ref_014_w2aab3b7c10b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Esquivel J, Piso P, Verwaal V, Bachleitner-Hofmann T, Glehen O, Gonzalez-Moreno S, et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol 2014;110:777\u20138.","DOI":"10.1002\/jso.23722"},{"key":"2025120909204647799_j_pp-2017-0003_ref_015_w2aab3b7c10b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435\u201343.","DOI":"10.1016\/j.ejso.2013.09.030"},{"key":"2025120909204647799_j_pp-2017-0003_ref_016_w2aab3b7c10b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Parietal peritonectomy. Ann Surg Oncol 2012;19:1250.","DOI":"10.1245\/s10434-012-2229-2"},{"key":"2025120909204647799_j_pp-2017-0003_ref_017_w2aab3b7c10b1b6b1ab2b1c17Aa","unstructured":"Sugarbaker P. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy: Textbook and video atlas. Woodbury, Connecticut, United States: Cin\u00e9-Med Publishing, 2012:214."},{"key":"2025120909204647799_j_pp-2017-0003_ref_018_w2aab3b7c10b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Van Der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am 2012;21:577\u201397.","DOI":"10.1016\/j.soc.2012.07.013"},{"key":"2025120909204647799_j_pp-2017-0003_ref_019_w2aab3b7c10b1b6b1ab2b1c19Aa","unstructured":"Sugarbaker PH, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: Pharmacological studies. Cancer Res 1990;50:5790\u20134."},{"key":"2025120909204647799_j_pp-2017-0003_ref_020_w2aab3b7c10b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Mahteme H, Von Heideman A, Grundmark B, Tholander B, Pahlman L, Glimelius B, et al. Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis. Eur J Surg Oncol 2008;34:547\u201352.","DOI":"10.1016\/j.ejso.2007.05.002"},{"key":"2025120909204647799_j_pp-2017-0003_ref_021_w2aab3b7c10b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Cashin PH, Mahteme H, Graf W, Karlsson H, Larsson R, Nygren P. Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer. BMC Cancer 2013;13:435.","DOI":"10.1186\/1471-2407-13-435"},{"key":"2025120909204647799_j_pp-2017-0003_ref_022_w2aab3b7c10b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Levine EA, Blazer DG, 3rd, Kim MK, Shen P, Stewart J, Guy C, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg 2012;214:599\u2013606; discussion -7.","DOI":"10.1016\/j.jamcollsurg.2011.12.028"},{"key":"2025120909204647799_j_pp-2017-0003_ref_023_w2aab3b7c10b1b6b1ab2b1c23Aa","unstructured":"Fujishima Y, Goi T, Kimura Y, Hirono Y, Katayama K, Yamaguchi A. MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer. Int J Oncol 2012;40:960\u20134."},{"key":"2025120909204647799_j_pp-2017-0003_ref_024_w2aab3b7c10b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Stewart J, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol 2008;15:2137\u201345.","DOI":"10.1245\/s10434-008-9967-1"},{"key":"2025120909204647799_j_pp-2017-0003_ref_025_w2aab3b7c10b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267\u201372.","DOI":"10.1093\/annonc\/mdf019"},{"key":"2025120909204647799_j_pp-2017-0003_ref_026_w2aab3b7c10b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Raynard B, Bonnay M, Pocard M. Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies. Eur J Surg Oncol 2006;32:607\u201313.","DOI":"10.1016\/j.ejso.2006.03.004"},{"key":"2025120909204647799_j_pp-2017-0003_ref_027_w2aab3b7c10b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"Elias D, El Otmany A, Bonnay M, Paci A, Ducreux M, Antoun S, et al. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 2002;63:346\u201352.","DOI":"10.1159\/000066229"},{"key":"2025120909204647799_j_pp-2017-0003_ref_028_w2aab3b7c10b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"Pomel C, Ferron G, Lorimier G, Rey A, Lhomme C, Classe JM, et al. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 2010;36:589\u201393.","DOI":"10.1016\/j.ejso.2010.04.005"},{"key":"2025120909204647799_j_pp-2017-0003_ref_029_w2aab3b7c10b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"Chalret Du Rieu Q, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: Correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol 2014;74:571\u201382.","DOI":"10.1007\/s00280-014-2525-6"},{"key":"2025120909204647799_j_pp-2017-0003_ref_030_w2aab3b7c10b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quenet F, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: Analysis of predictive factors. Ann Surg Oncol 2016;23:2315\u201322.","DOI":"10.1245\/s10434-016-5143-1"},{"key":"2025120909204647799_j_pp-2017-0003_ref_031_w2aab3b7c10b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"De Somer F, Ceelen W, Delanghe J, De Smet D, Vanackere M, Pattyn P, et al. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. Perit Dial Int 2008;28:61\u20136.","DOI":"10.1177\/089686080802800111"},{"key":"2025120909204647799_j_pp-2017-0003_ref_032_w2aab3b7c10b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: Identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res 2004;21:891\u20134.","DOI":"10.1023\/B:PHAM.0000026444.67883.83"},{"key":"2025120909204647799_j_pp-2017-0003_ref_033_w2aab3b7c10b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"Mehta AM, Van Den Hoven JM, Rosing H, Hillebrand MJ, Nuijen B, Huitema AD, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm 2015;479:23\u20137.","DOI":"10.1016\/j.ijpharm.2014.12.025"},{"key":"2025120909204647799_j_pp-2017-0003_ref_034_w2aab3b7c10b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 1998;55:130\u20138.","DOI":"10.1159\/000011847"},{"key":"2025120909204647799_j_pp-2017-0003_ref_035_w2aab3b7c10b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"Fujita T, Tamura T, Yamada H, Yamamoto A, Muranishi S. Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice. J Drug Target 1997;4:289\u201396.","DOI":"10.3109\/10611869708995844"},{"key":"2025120909204647799_j_pp-2017-0003_ref_036_w2aab3b7c10b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"Van Der Speeten K, Stuart OA, Chang D, Mahteme H, Sugarbaker PH. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2011;68:147\u201356.","DOI":"10.1007\/s00280-010-1460-4"},{"key":"2025120909204647799_j_pp-2017-0003_ref_037_w2aab3b7c10b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the management of peritoneal surface malignancy. Curr Oncol 2011;18:e84\u201396.","DOI":"10.3747\/co.v18i2.663"},{"key":"2025120909204647799_j_pp-2017-0003_ref_038_w2aab3b7c10b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"Levine EA, Stewart J, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1,000 patients. J Am Coll Surg 2014;218:573\u201385.","DOI":"10.1016\/j.jamcollsurg.2013.12.013"},{"key":"2025120909204647799_j_pp-2017-0003_ref_039_w2aab3b7c10b1b6b1ab2b1c39Aa","unstructured":"Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980;40:1165\u20138."},{"key":"2025120909204647799_j_pp-2017-0003_ref_040_w2aab3b7c10b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"De Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside. Recent Results Cancer Res 2007;169:53\u201373.","DOI":"10.1007\/978-3-540-30760-0_5"},{"key":"2025120909204647799_j_pp-2017-0003_ref_041_w2aab3b7c10b1b6b1ab2b1c41Aa","unstructured":"Witkamp A. Dose finding study of hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with carcinosis of colorectal origin. Eur J Surg Oncol 1998;136:699\u2013708."},{"key":"2025120909204647799_j_pp-2017-0003_ref_042_w2aab3b7c10b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2014;21:1501\u20135.","DOI":"10.1245\/s10434-013-3061-z"},{"key":"2025120909204647799_j_pp-2017-0003_ref_043_w2aab3b7c10b1b6b1ab2b1c43Aa","unstructured":"Dedrick RL, Myers CE, Bungay PM, DeVita VT, Jr.. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1\u201311."},{"key":"2025120909204647799_j_pp-2017-0003_ref_044_w2aab3b7c10b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"Rubin J, Clawson M, Planch A, Jones Q. Measurements of peritoneal surface area in man and rat. Am J Med Sci 1988;295:453\u20138.","DOI":"10.1097\/00000441-198805000-00007"},{"key":"2025120909204647799_j_pp-2017-0003_ref_045_w2aab3b7c10b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003;12:755\u201369, xiv.","DOI":"10.1016\/S1055-3207(03)00051-6"},{"key":"2025120909204647799_j_pp-2017-0003_ref_046_w2aab3b7c10b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Stuart OA, Carmignani CP. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 2006;57:703\u20138.","DOI":"10.1007\/s00280-005-0074-8"},{"key":"2025120909204647799_j_pp-2017-0003_ref_047_w2aab3b7c10b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"Mas-Fuster MI, Ramon-Lopez A, Nalda-Molina R. Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): A pharmacodynamic point of view. Cancer Chemother Pharmacol 2013;72:273\u20134.","DOI":"10.1007\/s00280-013-2204-z"},{"key":"2025120909204647799_j_pp-2017-0003_ref_048_w2aab3b7c10b1b6b1ab2b1c48Aa","unstructured":"Los G, Mutsaers PH, Van Der Vijgh WJ, Baldew GS, De Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res 1989;49:3380\u20134."},{"key":"2025120909204647799_j_pp-2017-0003_ref_049_w2aab3b7c10b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"Conti M, De Giorgi U, Tazzari V, Bezzi F, Baccini C. Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. J Chemother 2004;16:23\u20135.","DOI":"10.1080\/1120009X.2004.11782377"},{"key":"2025120909204647799_j_pp-2017-0003_ref_050_w2aab3b7c10b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"Gladieff L, Chatelut E, Dalenc F, Ferron G. Pharmacological bases of intraperitoneal chemotherapy. Bull Cancer 2009;96:1235\u201342.","DOI":"10.1684\/bdc.2009.0982"},{"key":"2025120909204647799_j_pp-2017-0003_ref_051_w2aab3b7c10b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol 2014;40:12\u201326.","DOI":"10.1016\/j.ejso.2013.10.019"},{"key":"2025120909204647799_j_pp-2017-0003_ref_052_w2aab3b7c10b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"Alberts DS, Liu PY, Hannigan EV, O\u2019Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950\u20135.","DOI":"10.1056\/NEJM199612263352603"},{"key":"2025120909204647799_j_pp-2017-0003_ref_053_w2aab3b7c10b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34\u201343.","DOI":"10.1056\/NEJMoa052985"},{"key":"2025120909204647799_j_pp-2017-0003_ref_054_w2aab3b7c10b1b6b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al. HIPEC ROC I: A phase i study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 2014;136(3): 699\u2013708.","DOI":"10.1002\/ijc.29011"},{"key":"2025120909204647799_j_pp-2017-0003_ref_055_w2aab3b7c10b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"Hakeam HA, Breakiet M, Azzam A, Nadeem A, Amin T. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery. Ren Fail 2014;36:1486\u201391.","DOI":"10.3109\/0886022X.2014.949758"},{"key":"2025120909204647799_j_pp-2017-0003_ref_056_w2aab3b7c10b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999;15:79\u2013107.","DOI":"10.1080\/026567399285765"},{"key":"2025120909204647799_j_pp-2017-0003_ref_057_w2aab3b7c10b1b6b1ab2b1c57Aa","doi-asserted-by":"crossref","unstructured":"Van Der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol 2011;2011:185092.","DOI":"10.1155\/2011\/185092"},{"key":"2025120909204647799_j_pp-2017-0003_ref_058_w2aab3b7c10b1b6b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"Deraco M, Baratti D, Cabras AD, Zaffaroni N, Perrone F, Villa R, et al. Experience with peritoneal mesothelioma at the Milan National Cancer Institute. World J Gastrointest Oncol 2010;2:76\u201384.","DOI":"10.4251\/wjgo.v2.i2.76"},{"key":"2025120909204647799_j_pp-2017-0003_ref_059_w2aab3b7c10b1b6b1ab2b1c59Aa","doi-asserted-by":"crossref","unstructured":"Tritton TR. Cell surface actions of adriamycin. Pharmacol Ther 1991;49:293\u2013309.","DOI":"10.1016\/0163-7258(91)90060-Y"},{"key":"2025120909204647799_j_pp-2017-0003_ref_060_w2aab3b7c10b1b6b1ab2b1c60Aa","doi-asserted-by":"crossref","unstructured":"Triton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982;217:248\u201350.","DOI":"10.1126\/science.7089561"},{"key":"2025120909204647799_j_pp-2017-0003_ref_061_w2aab3b7c10b1b6b1ab2b1c61Aa","unstructured":"Lane P, Vichi P, Bain DL, Tritton TR. Temperature dependence studies of adriamycin uptake and cytotoxicity. Cancer Res 1987;47:4038\u201342."},{"key":"2025120909204647799_j_pp-2017-0003_ref_062_w2aab3b7c10b1b6b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"Van Der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol 2009;63:799\u2013805.","DOI":"10.1007\/s00280-008-0800-0"},{"key":"2025120909204647799_j_pp-2017-0003_ref_063_w2aab3b7c10b1b6b1ab2b1c63Aa","unstructured":"Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, et al. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982;42:4265\u20139."},{"key":"2025120909204647799_j_pp-2017-0003_ref_064_w2aab3b7c10b1b6b1ab2b1c64Aa","unstructured":"Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979;39:3209\u201314."},{"key":"2025120909204647799_j_pp-2017-0003_ref_065_w2aab3b7c10b1b6b1ab2b1c65Aa","unstructured":"Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Fisher RI, et al. Chemotherapy for murine ovarian cancer: A rationale for ip therapy with adriamycin. Cancer Treat Rep 1979;63:269\u201373."},{"key":"2025120909204647799_j_pp-2017-0003_ref_066_w2aab3b7c10b1b6b1ab2b1c66Aa","unstructured":"Nagai K, Nogami S, Egusa H, Konishi H. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats. Pharmazie 2014;69:125\u20137."},{"key":"2025120909204647799_j_pp-2017-0003_ref_067_w2aab3b7c10b1b6b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"Harrison LE, Bryan M, Pliner L, Saunders T. Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy. Ann Surg Oncol 2008;15:1407\u201313.","DOI":"10.1245\/s10434-007-9718-8"},{"key":"2025120909204647799_j_pp-2017-0003_ref_068_w2aab3b7c10b1b6b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, et al. Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis. Drug Metab Dispos 2012;40:2365\u201373.","DOI":"10.1124\/dmd.112.047480"},{"key":"2025120909204647799_j_pp-2017-0003_ref_069_w2aab3b7c10b1b6b1ab2b1c69Aa","doi-asserted-by":"crossref","unstructured":"Van Der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol 2010;102:730\u20135.","DOI":"10.1002\/jso.21702"},{"key":"2025120909204647799_j_pp-2017-0003_ref_070_w2aab3b7c10b1b6b1ab2b1c70Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 2004;22:3284\u201392.","DOI":"10.1200\/JCO.2004.10.012"},{"key":"2025120909204647799_j_pp-2017-0003_ref_071_w2aab3b7c10b1b6b1ab2b1c71Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Benizri E, Di Pietrantonio D, Menegon P, Malka D, Raynard B. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007;14:509\u201314.","DOI":"10.1245\/s10434-006-9167-9"},{"key":"2025120909204647799_j_pp-2017-0003_ref_072_w2aab3b7c10b1b6b1ab2b1c72Aa","doi-asserted-by":"crossref","unstructured":"McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC + EPIC versus HIPEC-alone: Differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 2013;107:591\u20136.","DOI":"10.1002\/jso.23276"},{"key":"2025120909204647799_j_pp-2017-0003_ref_073_w2aab3b7c10b1b6b1ab2b1c73Aa","doi-asserted-by":"crossref","unstructured":"Tan GH, Ong WS, Chia CS, Tham CK, Soo KC, Teo MC. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?. Int J Hyperthermia 2016;32:281\u20138.","DOI":"10.3109\/02656736.2015.1135485"},{"key":"2025120909204647799_j_pp-2017-0003_ref_074_w2aab3b7c10b1b6b1ab2b1c74Aa","doi-asserted-by":"crossref","unstructured":"Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663\u20136.","DOI":"10.1038\/179663a0"},{"key":"2025120909204647799_j_pp-2017-0003_ref_075_w2aab3b7c10b1b6b1ab2b1c75Aa","doi-asserted-by":"crossref","unstructured":"Muggia FM, Peters GJ, Landolph JR, Jr.. XIII International Charles Heidelberger Symposium and 50 years of fluoropyrimidines in cancer therapy held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009;8:992\u20139.","DOI":"10.1158\/1535-7163.MCT-08-0731"},{"key":"2025120909204647799_j_pp-2017-0003_ref_076_w2aab3b7c10b1b6b1ab2b1c76Aa","doi-asserted-by":"crossref","unstructured":"Wagner PL, Jones D, Aronova A, Shia J, Weiser MR, Temple LK, et al. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis. Dis Colon Rectum 2012;55:407\u201315.","DOI":"10.1097\/DCR.0b013e3182468330"},{"key":"2025120909204647799_j_pp-2017-0003_ref_077_w2aab3b7c10b1b6b1ab2b1c77Aa","doi-asserted-by":"crossref","unstructured":"Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomized trial. World J Surg 2001;25:985\u201390.","DOI":"10.1007\/s00268-001-0067-7"},{"key":"2025120909204647799_j_pp-2017-0003_ref_078_w2aab3b7c10b1b6b1ab2b1c78Aa","doi-asserted-by":"crossref","unstructured":"Kwon OK, Chung HY, Yu W. Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients. Cancer Res Treat 2014;46:270\u20139.","DOI":"10.4143\/crt.2014.46.3.270"},{"key":"2025120909204647799_j_pp-2017-0003_ref_079_w2aab3b7c10b1b6b1ab2b1c79Aa","doi-asserted-by":"crossref","unstructured":"Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. J Surg Oncol 2016;113:796\u2013803.","DOI":"10.1002\/jso.24248"},{"key":"2025120909204647799_j_pp-2017-0003_ref_080_w2aab3b7c10b1b6b1ab2b1c80Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Mora JT, Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist 2005;10:112\u201322.","DOI":"10.1634\/theoncologist.10-2-112"},{"key":"2025120909204647799_j_pp-2017-0003_ref_081_w2aab3b7c10b1b6b1ab2b1c81Aa","doi-asserted-by":"crossref","unstructured":"Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: New compounds, binding modes and cellular activities. Nat Prod Rep 2014;31:335\u201355.","DOI":"10.1039\/C3NP70092E"},{"key":"2025120909204647799_j_pp-2017-0003_ref_082_w2aab3b7c10b1b6b1ab2b1c82Aa","doi-asserted-by":"crossref","unstructured":"De Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: From laboratory bench to bedside. Cancer Treat Rev 2006;32:471\u201382.","DOI":"10.1016\/j.ctrv.2006.07.006"},{"key":"2025120909204647799_j_pp-2017-0003_ref_083_w2aab3b7c10b1b6b1ab2b1c83Aa","doi-asserted-by":"crossref","unstructured":"Mohamed F, Sugarbaker PH. Intraperitoneal taxanes. Surg Oncol Clin N Am 2003;12:825\u201333.","DOI":"10.1016\/S1055-3207(03)00038-3"},{"key":"2025120909204647799_j_pp-2017-0003_ref_084_w2aab3b7c10b1b6b1ab2b1c84Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Bandou E, Sawa T, Yoshimitsu Y, Endou Y, Sasaki T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol 2006;32:661\u20135.","DOI":"10.1016\/j.ejso.2006.03.007"},{"key":"2025120909204647799_j_pp-2017-0003_ref_085_w2aab3b7c10b1b6b1ab2b1c85Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res 1996;82:317\u201325.","DOI":"10.1007\/978-1-4613-1247-5_20"},{"key":"2025120909204647799_j_pp-2017-0003_ref_086_w2aab3b7c10b1b6b1ab2b1c86Aa","unstructured":"Zylberberg B, Dormont D, Janklewicz S, Darai E, Bretel JJ, Poncelet C, et al. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. Eur J Gynaecol Oncol 2001;22:40\u20135."},{"key":"2025120909204647799_j_pp-2017-0003_ref_087_w2aab3b7c10b1b6b1ab2b1c87Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal\/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol 2012;2012:148420.","DOI":"10.1155\/2012\/148420"},{"key":"2025120909204647799_j_pp-2017-0003_ref_088_w2aab3b7c10b1b6b1ab2b1c88Aa","unstructured":"Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631\u20136."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/2\/2\/article-p63.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0003\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:43:49Z","timestamp":1765277029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2017-0003\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":88,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6,6]]},"published-print":{"date-parts":[[2017,6,5]]}},"alternative-id":["10.1515\/pp-2017-0003"],"URL":"https:\/\/doi.org\/10.1515\/pp-2017-0003","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}